25,919 reports of this reaction
13.2% of all TIRZEPATIDE reports
#1 most reported adverse reaction
INCORRECT DOSE ADMINISTERED is the #1 most commonly reported adverse reaction for TIRZEPATIDE, manufactured by Eli Lilly and Company. There are 25,919 FDA adverse event reports linking TIRZEPATIDE to INCORRECT DOSE ADMINISTERED. This represents approximately 13.2% of all 196,029 adverse event reports for this drug.
TIRZEPATIDE has an overall safety score of 78 out of 100. Patients taking TIRZEPATIDE who experience incorrect dose administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INCORRECT DOSE ADMINISTERED is a frequently reported adverse event for TIRZEPATIDE, accounting for a significant proportion of all reports.
In addition to incorrect dose administered, the following adverse reactions have been reported for TIRZEPATIDE:
The following drugs have also been linked to incorrect dose administered in FDA adverse event reports:
INCORRECT DOSE ADMINISTERED has been reported as an adverse event in 25,919 FDA reports for TIRZEPATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INCORRECT DOSE ADMINISTERED accounts for approximately 13.2% of all adverse event reports for TIRZEPATIDE, making it one of the most commonly reported side effect.
If you experience incorrect dose administered while taking TIRZEPATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.